The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
However, not all companies with momentum are long-term winners, and many investors have lost money by following short-term trends. On that note, here are three stocks getting more buzz than they deserve and some you should buy instead.
Progyny (PGNY)
One-Month Return: +17%
Pioneering a data-driven approach to family building that has achieved an industry-leading patient satisfaction score of +80, Progyny (NASDAQ: PGNY) provides comprehensive fertility and family building benefits solutions to employers, helping employees access quality fertility treatments and support services.
Why Does PGNY Worry Us?
- Subscale operations are evident in its revenue base of $1.27 billion, meaning it has fewer distribution channels than its larger rivals
- Below-average returns on capital indicate management struggled to find compelling investment opportunities
Progyny is trading at $23.90 per share, or 12.9x forward P/E. Check out our free in-depth research report to learn more about why PGNY doesn’t pass our bar.
IQVIA (IQV)
One-Month Return: +8.7%
Created from the 2016 merger of Quintiles (a clinical research organization) and IMS Health (a healthcare data specialist), IQVIA (NYSE: IQV) provides clinical research services, data analytics, and technology solutions to help pharmaceutical companies develop and market medications more effectively.
Why Do We Think Twice About IQV?
- Scale is a double-edged sword because it limits the company’s growth potential compared to its smaller competitors, as reflected in its below-average annual revenue increases of 3.5% for the last two years
- Constant currency growth was below our standards over the past two years, suggesting it might need to invest in product improvements to get back on track
- Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 3.6 percentage points
IQVIA’s stock price of $221.52 implies a valuation ratio of 17.3x forward P/E. Read our free research report to see why you should think twice about including IQV in your portfolio.
Hartford (HIG)
One-Month Return: +3%
Recognizable by its iconic stag logo that dates back to 1810, The Hartford (NYSE: HIG) provides property and casualty insurance, group benefits, and investment products to individuals and businesses across the United States.
Why Are We Hesitant About HIG?
- Large revenue base constrains its growth potential, as seen in its unexciting 6.1% annualized increases in net premiums earned over the last five years fell below our expectations for the insurance sector
- Projected sales decline of 25.7% for the next 12 months points to a tough demand environment ahead
- Annual book value per share growth of 5.8% over the last five years lagged behind its insurance peers as its large balance sheet made it difficult to generate incremental capital growth
At $132.63 per share, Hartford trades at 2x forward P/B. To fully understand why you should be careful with HIG, check out our full research report (it’s free for active Edge members).
Stocks We Like More
If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.
Don’t wait for the next volatility shock. Check out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
